Epigral Intrinsic Value
Epigral (EPIGRAL) median intrinsic value is ₹569.30 from 9 valuation models (range ₹330–₹1257), vs current price ₹1101.20 — -48.3% downside (Trading Above Calculated Value), margin of safety -93.4%. For current market price and key ratios, visit Epigral stock price NSE.
EPIGRAL Valuation Methods Summary — DCF, Graham Number & P/E
Epigral intrinsic value across 9 models vs current price ₹1101.20 — upside/downside and value range per method. Read Epigral dividend payments for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹569.76 | ₹455.81 - ₹683.71 | -48.3% | EPS: ₹47.48, Sector P/E: 12x |
| Book Value Method | asset | ₹443.02 | ₹398.72 - ₹487.32 | -59.8% | Book Value/Share: ₹443.02, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹438.33 | ₹394.50 - ₹482.16 | -60.2% | Revenue/Share: ₹547.91, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹747.91 | ₹673.12 - ₹822.70 | -32.1% | EBITDA: ₹536.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹1257.25 | ₹1005.80 - ₹1508.70 | +14.2% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹330.36 | ₹297.32 - ₹363.40 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹391.24 | ₹352.12 - ₹430.36 | -64.5% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹569.30 | ₹512.37 - ₹626.23 | -48.3% | ROE: 10.7%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹687.95 | ₹619.16 - ₹756.75 | -37.5% | EPS: ₹47.48, BVPS: ₹443.02 |
EPIGRAL Intrinsic Value vs Market Price — All Valuation Models
Epigral fair value range ₹330–₹1257 vs current market price ₹1101.20 across 9 valuation models. Analyse Epigral shareholding analysis to track promoter, FII and institutional holdings.
EPIGRAL Intrinsic Value Analysis — Undervalued or Overvalued?
Epigral median intrinsic value ₹569.30, current price ₹1101.20 — Trading Above Calculated Value by 48.3%, margin of safety -93.4%.
What is the intrinsic value of EPIGRAL?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Epigral (EPIGRAL) is ₹569.30 (median value). With the current market price of ₹1101.20, this represents a -48.3% variance from our estimated fair value.
The valuation range spans from ₹330.36 to ₹1257.25, indicating ₹330.36 - ₹1257.25.
Is EPIGRAL undervalued or overvalued?
Based on our multi-method analysis, Epigral (EPIGRAL) appears to be trading above calculated value by approximately 48.3%.
EPIGRAL Financial Health — Key Ratios vs Industry Benchmarks
Epigral financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.03 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 10.7% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 22.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.75x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
EPIGRAL Cash Flow Quality — Operating & Free Cash Flow
Epigral operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2024 | ₹398 Cr | ₹198 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹626 Cr | ₹408 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹284 Cr | ₹57 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹229 Cr | ₹131 Cr | Positive Free Cash Flow | 8/10 |